Oxcarbazepine in the treatment of epilepsy: An open-labelled, prospective, post-marketing surveillance study with oxcarbazepine in the treatment of 1385 patients with epilepsy;Oxcarbazepin in der epilepsietherapie: Multizentrische anwendungsbeobachtung mit 1385 epilepsie-patienten zur neueinstellung oder umstellung auf oxcarbazepin

Fortschritte der Neurologie Psychiatrie

Volumn 75, Issue 2, 2007, Pages 100-106

  Freidel, M ^a   Krause, E ^b   Kuhn, Katrin ^c   Peper, R ^d   Vogel, H ^b  

^a Facharzt für Neurologie und Psychiatrie ^*  (Germany)

^b Fachärztin für Neurologie und Psychiatrie   (Germany)

^c ALK SCHERAX Arzneimittel GmbH   (Germany)

^d Facharzt für Neurologie und Psychiatrie   (Germany)

Author keywords

Epilepsy; Oxcarbazepine; Post marketing surveillance study

Indexed keywords

CARBAMAZEPINE; OXCARBAZEPINE; ANTICONVULSIVE AGENT; DRUG DERIVATIVE;

ADD ON THERAPY; ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CLINICAL PRACTICE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; EPILEPSY; FEMALE; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; UNSPECIFIED SIDE EFFECT; MIDDLE AGED; POSTMARKETING SURVEILLANCE; PRESCHOOL CHILD; PROSPECTIVE STUDY; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTICONVULSANTS; CARBAMAZEPINE; CHILD; CHILD, PRESCHOOL; EPILEPSY; FEMALE; HUMANS; INFANT; MALE; MIDDLE AGED; PRODUCT SURVEILLANCE, POSTMARKETING; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 34247152864     PISSN: 07204299     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2006-932218     Document Type: Article

References (18)

1. Schmidt D, Elger CE. What is the evidence that oxcarbazepine and carbamazepine are distinctly different antiepileptic drugs? Epilepsy Behav 2004; 5(5): 627-635
2. Glauser TA. Oxcarbazepine in the treatment of epilepsy. Pharmacotherapy 2001; 21 (8): 904-919
3. Wellington K Goa KL. Oxcarbazepine: an update of its efficacy in the management of epilepsy. CNS Drugs 2001; 15(2): 137-163
4. Bang LM, Goa KL. Spotlight on oxcarbazepine in epilepsy. CNS Drugs 2004; 18(1): 57-61
5. Beydoun A, Kutluay E. Oxcarbazepine. Expert Opin Pharmacother 2002; 3(1): 59-71
6. Kalis MM, Huff NA. Oxcarbazepine, an antiepileptic agent. Clin Ther 2001; 23 (5): 680-700 discussion 645
7. Sachdeo R, Beydoun A, Schachter S, Vazquez B, Schaul N, Mesenbrink P et al. Oxcarbazepine (Trileptal) as monotherapy in patients with partial seizures. Neurology 2001; 57 (5): 864-871
8. Rijckevorsel K van, Boon PA. The 'number needed to treat' with Levetiracetam (LEV): comparison with the other new antiepileptic drugs (AEDs). Seizure 2001; 10 (3): 235-236
9. Serdaroglu G, Kurul S, Tutuncuoglu S, Dirik E, Sarioglu B. Oxcarbazepine in the treatment of childhood epilepsy. Pediatr Neurol 2003; 28 (1): 37-41
10. Sander J. First-line treatments for partial and generalised seizures: a systematic evidence-based review of their efficacy and tolerability. Epilepsia 2002; 43 (Suppl. 8): 113
11. Clemens B, Menes A, Nagy Z. Objective assessment of neurotoxicity while shifting from carbamazepine to oxcarbazepine. Acta Neurol Scand 2004; 109(5): 324-329
12. Smith PE. Clinical recommendations for oxcarbazepine. Seizure 2001; 10 (2): 87-91
13. Amelsvoort T Van, Bakshi R, Devaux CB, Schwabe S. Hyponatremia associated with carbamazepine and oxcarbazepine therapy: a review. Epilepsia 1994; 35 (1): 181-188
14. Kutluay E, McCague K, D'Souza J, Beydoun A. Safety and tolerability of oxcarbazepine in elderly patients with epilepsy. Epilepsy Behav 2003; 4(2): 175-180
15. Opstal JM van, Janknegt R, Cilissen J, L'Ortije WH, Nel JE, De Heer F. Severe overdosage with the antiepileptic drug oxcarbazepine. Br J Clin Pharmacol 2004; 58 (3): 329-331
16. Albani F, Grassi B, Ferrara R, Turrini R, Baruzzi A. Immediate (overnight) switching from carbamazepine to oxcarbazepine monotherapy is equivalent to a progressive switch. Seizure 2004; 13 (4): 254-263
17. Homberg V, Kowalik A, Schulze-Bonhage A. Ad hoc-Umstellung von Carbamazepin auf Oxcarbazepin - Effektivität und Tolerabilität. Nervenarzt 2001; 72 (12): 918-923
18. Schmidt D, Arroyo S, Baulac M, Dam M, Dulac O, Friis ML et al. Recommendations on the clinical use of oxcarbazepine in the treatment of epilepsy: a consensus view. Acta Neurol Scand 2001; 104 (3): 167-170